Oral GLP-1 treatments / working resource
Primary source desk
Keep the original documents and the limits of their conclusions within reach.
Start with the product-specific question
Peptide tablets versus small-molecule GLP-1 medicines
The oral-treatment specialist, with molecule and formulation distinctions. What should I know about peptide tablets versus small-molecule glp-1 medicines?
Open the Oral GLP-1s library ↗The June 2026 US Wegovy label includes oral tablets for long-term adult weight reduction and cardiovascular risk reduction in specified adults, with diet and physical activity.
Read the original record ↗
The original record comes first.
These are starting points for the Oral GLP-1s library. Read the source's exact question, product, population and date. A source can be authoritative for one claim and irrelevant to another.
Keep claims and sources together.
The June 2026 US Wegovy label includes oral tablets for long-term adult weight reduction and cardiovascular risk reduction in specified adults, with diet and physical activity.
Supporting record ↗Wegovy tablets are swallowed whole and have empty-stomach and post-dose waiting requirements in their own label.
Supporting record ↗OASIS4 randomized 307 adults without diabetes; at week 64 mean weight change was−13.6% with the 25 mg daily trial tablet versus−2.2% with placebo.
Supporting record ↗OASIS4 gastrointestinal adverse events occurred in 74.0% with the oral tablet versus 42.2% with placebo.
Supporting record ↗These fields stay in this page until you leave or reload. No notes are saved or transmitted. Print a copy if you want to keep your work. Educational organization tools do not replace clinical advice.